Filing summary
Period and issuer: The supplied filing is IsoRay, Inc.’s Form 10-K for the fiscal year ended June 30, 2015, filed September 14, 2015. This does not match the request metadata identifying Perspective Therapeutics or “2014 Q4”; the filing itself reports no such issuer or period.
Business context
IsoRay develops, manufactures, and sells Cesium-131 cancer-treatment products, principally Proxcelan brachytherapy seeds, and the GliaSite brain-radiation therapy system. The company reported one operating segment. Its business remained heavily dependent on prostate cancer seed sales; management was also pursuing brain, lung, gynecological, and other applications.
Financial performance and position
| Metric | FY2015 | FY2014 |
|---|---|---|
| Product sales | $4.61 million | $4.22 million |
| Gross profit/(loss) | $167,393 | $(196,471) |
| Gross margin | 3.6% | (4.7%) |
| Operating loss | $(4.34) million | $(4.59) million |
| Net loss | $(3.68) million | $(5.96) million |
| Net loss per share | $(0.07) | $(0.16) |
| Operating cash used | $(3.52) million | $(3.23) million |
Annual sales increased 9%; management attributed the improvement mainly to seed brachytherapy growth, including 13% growth in prostate treatments. Fourth-quarter FY2015 sales were $1.34 million, versus $949,516 in the prior-year quarter; fourth-quarter gross profit was $204,962, while net loss was $1.03 million.
At June 30, 2015, cash and cash equivalents were $5.23 million, current certificates of deposit were $9.36 million, and non-current certificates of deposit were $5.11 million. Working capital was approximately $15.23 million; total assets were $23.00 million and total liabilities $2.22 million. No conventional borrowings are identified in the supplied balance sheet; liabilities included a $947,849 asset-retirement obligation and a $181,000 warrant derivative liability. Cash and investments totaled approximately $19.70 million. The company reported no income-tax provision or benefit and fully reserved its deferred tax assets.
Changes, outlook, and risks
- Sales recovered from FY2014, and gross results returned to positive territory, but operating losses continued. Net loss improved partly because FY2015 included a $374,605 gain from the change in warrant derivative fair value, compared with a $1.38 million loss in FY2014.
- Prostate products represented 87% of FY2015 revenue. Five customers/facility groups accounted for approximately 49.5%; the largest represented 24.16%. GliaSite revenue fell 57% year over year and made up 2% of sales.
- Management said available cash and investments, together with projected sales, should fund operations for at least 12 months and, at current revenue and expense levels, five years. It estimated break-even at about $750,000 monthly revenue and operating cash-flow break-even at about $700,000 per month, while cautioning there was no assurance these targets would be achieved. These are management estimates, not formal sales guidance.
- Key supply risk: approximately 83% of FY2015 Cesium-131 came from a Russian supplier under a contract ending January 31, 2016. Management cited domestic MURR production and enriched-barium inventory as mitigation, but future supply, volumes, and pricing remained uncertain.
- Other material risks include continuing losses and operating cash burn, market acceptance and clinical evidence, reimbursement changes, competition and declining brachytherapy market share, reliance on a small customer base and sole-source components, and foreign-exchange and Russia-related disruption risks.
- A securities class action was filed in May 2015 concerning a company press release about a published lung-cancer article. The complaints were consolidated; the company said it would defend the claims, but could not estimate the outcome or damages. The filing also describes a disputed potential royalty claim and possible costs to decommission the leased manufacturing facility.
- After year-end, the company agreed to buy adjacent land for $168,000 and outlined development obligations, including construction within two years, use as its primary production facility for ten years, and employment of at least 25 full-time workers. Failure to meet the covenants could trigger a payment tied to the property’s appraised value.
Important facts for investors to verify
- Confirm the issuer and reporting period: the source is IsoRay’s FY2015 10-K, not a Perspective Therapeutics 2014 Q4 filing.
- Check whether the sales recovery continued, especially prostate-seed growth, customer concentration, and the contribution of non-prostate products.
- Verify the Russian supply contract’s renewal or replacement, domestic production capacity, and the remaining usable enriched-barium supply.
- Assess the basis and sensitivity of management’s five-year runway and monthly break-even estimates against ongoing operating cash burn and planned facility investment.
- Track the securities litigation, potential facility decommissioning costs, and the land-purchase development covenants.
- Review dilution exposure: the filing reported 2.42 million outstanding options and 385,800 warrants at June 30, 2015, alongside approximately 55.0 million common shares outstanding as of September 11, 2015.